本次荟萃分析旨在研究鼻窦腺样囊性癌（snAdCC）的结果。我们按照PRISMA指南进行研究，并纳入了报道snAdCC 5年总生存率（OS）的研究。通过文献搜索确定符合条件的研究，并使用JBI临床评价清单进行评估。共纳入了17个研究，共计2259例患者（平均年龄：58.1岁，女性占52.7%，男性占47.3%）。荟萃分析结果显示，5年总生存率、10年总生存率和5年无病生存率分别为68%，40%和47.2%。研究层面的描述性统计结果显示，诊断时局部晚期肿瘤分别占23%的cT3、53%的cT4、3.4%的N+和4.2%的M+。肿瘤中有29.7%位于鼻腔，67.6%位于副鼻窦。最上颌窦、筛窦、蝶窦和额窦分别占50.9%、7.2%、4%和0.5%。45.4%的患者接受手术和放疗联合治疗，19.3%的患者仅接受手术治疗。综上所述，这些结果强调了对snAdCC患者进行彻底监测的重要性，以便发现疾病的任何可能复发或进展。

This meta-analysis aims to investigate the outcome of sinonasal adenoid cystic carcinoma (snAdCC). We followed PRISMA guidelines and included studies reporting 5-year overall survival (OS) rates for snAdCC. Eligible studies were identified through a literature search and assessed using JBI critical appraisal checklist. A total of 17 studies were included comprising 2259 patients (mean age: 58.1 years, 52.7% female, 47.3% male). The meta-analysis demonstrated that the 5-year OS, 10-year OS, and 5-year disease-free survival (DFS) were 68%, 40%, and 47.2%, respectively. Descriptive statistics on study level showed high rates of locally advanced tumor stages at diagnosis: 23% cT3, 53% cT4, 3.4% N+, and 4.2% M+. 29.7% of the tumors were in the nasal cavity, 67.6% in the paranasal sinuses. The maxillary, ethmoid, sphenoid, and frontal sinus were affected in 50.9%, 7.2%, 4%, and 0.5%, of cases. A combination of surgery and radiotherapy was used in 45.4% of the patients and 19.3% of patients received surgery only. In conclusion, these findings emphasize the significance of thorough surveillance for individuals with snAdCC to identify any potential recurrence or progression of the disease.